Effects of Rhinophototherapy on Quality of Life in Persistant Allergic Rhinitis

Tatar, Emel Çadallı; Korkmaz, Hakan; Sürenoğlu, Ünzile Akpınar; Saylam, Güleser; Özdek, Ali

doi:10.3342/ceo.2013.6.2.73

Cited by 13 publications

(11 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Many individuals with disease do not report their complaints or seek treatment [3]. Accordingly, AR is considered a social problem that negatively affects patients' quality of life and performance [4]. Recently, on the basis of frequency and duration of symptoms, AR has been categorized as either intermittent or persistent [5].…”

Section: Introductionmentioning

confidence: 99%

Evidence for eosinophil and IL-17 mediated inflammation in allergic rhinitis

et al. 2020

View full text Add to dashboard Cite

Background: The aim was to determine the level of inflammatory cytokines, eosinophil cationic protein and IgE in allergic rhinitis (AR) patients. Subjects and methods: Blood samples were taken from 88 AR patients and 88 healthy controls (HC). Each sample was analysed for eosinophil counts by flow cytometry, IgE by ECLIA, ECP, IL-17, and IL-33 by using ELISA test. Results: There was no significant difference between AR patients and the control group in age and gender. Levels of eosinophils, IgE, ECP, IL-17, IL-33 and the total symptom scores were significantly higher in AR patients than the HC (P = 0.0001). Serum ECP correlated with IL-17 (P = 0.041, r = 0.42), IL-33 (P = 0.0001, r = 080), and IgE levels (P = 0.017, r = 0.45) in the R patients. There was no correlation between IL-17 and IL-33. There was a correlation between symptom scores and eosinophils (P = 0.026, r = 0.52), and IgE (P = 0.001, r = 0.60) in the patients. No correlation was observed between symptom scores and ECP, IL-17, and IL-33 in the AR patient. Conclusions: Patients with AR have significant higher serum levels of ECP, IL-17, and IL-33 than healthy controls. This indicates that these markers could be used to in order to diagnose AR and to monitor disease. Inhibitory molecules to IL-17 and IL-33 may be considered as novel treatment strategies.

show abstract

Section: Introductionmentioning

confidence: 99%

Evidence for eosinophil and IL-17 mediated inflammation in allergic rhinitis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Tatar et al reported that rhinophototherapy paired with medical therapy (topical mometasone furoate and oral levocetirizine) had a better effect on allergic rhinitis symptoms, including nasal obstruction, than did medical therapy on its own [14]. Our results show that all rhinitis symptoms, including nasal congestion, significantly improved 30 minutes after a single RLRPT treatment, but worsened again, particularly for sneezing, 2 days later even under medical treatment.…”

Section: Discussionmentioning

confidence: 54%

Effect of Red Light Rhinophototherapy on Nasal Patency in Patients with Allergic Rhinitis

Jiang

Wang

2018

International Journal of Otolaryngology

View full text Add to dashboard Cite

Purpose The effect of red light rhinophototherapy (RLRPT) on nasal patency in patients with a clinical diagnosis of allergic rhinitis was investigated. Materials and Methods Subjects were randomly divided into 2 groups, with patients in one group given one treatment session of RLRPT, followed by medical treatment. Those in the second group were treated with medical treatment only. The rhinitis symptoms were evaluated both before and 30 minutes after RLRPT and 2 days later. The nasal patency was objectively measured through the use of both active anterior rhinomanometry and acoustic rhinometry before and 30 minutes after RLRPT. Results All rhinitis symptoms, including nasal congestion, significantly improved 30 minutes after a single RLRPT treatment, but worsened again, particularly for sneezing, 2 days later. Nasal resistance slightly decreased 30 minutes after RLRPT. The first minimal cross-sectional area did not change after RLRPT, but the second minimal cross-sectional area with the volume of the nasal cavity between 2.0 and 5.0 cm from the tip of the nosepiece significantly lessened. Conclusions This study showed that RLRPL did not objectively improve patient's nasal patency. Registration Number The trial is registered with NCT03752645.

show abstract

“…When these adverse effects are taken into account, intranasal phototherapy may be an option in the treatment of allergic rhinitis. Only one study has evaluated the additive effect of rhinophototherapy in patients receiving nasal corticosteroids and antihistamines; the authors reported that improvements in a quality of life questionnaire, nasal symptom scores, and VAS were statistically significant in the rhinophototherapy group [17]. To our knowledge this is the first study that compares the histopathological effects of intranasal phototherapy and nasal steroids.…”

Section: Discussionmentioning

confidence: 94%